Attached files
| file | filename |
|---|---|
| EX-99.1 - WORLD HEART CORP | v207897_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
—————————————
FORM
8-K
—————————————
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported) January 12, 2011
______________________________
WORLD
HEART CORPORATION
(Exact
name of registrant as specified in charter)
|
Delaware
|
000-28882
|
52-2247240
|
||
|
(State
or other jurisdiction of
incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
|
4750
Wiley Post Way, Suite 120, Salt Lake City, UT
|
84116
|
|||
|
(Address
of principal executive offices)
|
(Zip
Code)
|
(801)
355-6255
Registrant’s
telephone number, including area code
Not
Applicable
(Former
name or former address, if changed since last report)
______________________
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR
240.13e-4(c))
Item 8.01.
Other Events.
On
January 12, 2011, World Heart Corporation announced that Tampa
General Hospital (Tampa General) in Tampa, Florida has successfully
implanted its first Levacor® Ventricular Assist Device (VAD). This is
the fifteenth implant with the Levacor VAD since the inception of the BTT
study.
WorldHeart
also announced that three refinements are being made to its Levacor VAD based on
initial experience. It can be expected that enrollment will
continue to be slow in the BTT Study until the refinements are
completed. These refinements are the positioning of the
inflow cannula into the ventricle, the elimination of a false alarm that has led
to controller exchanges and the optimization of surface manufacturing processes. WorldHeart
expects that implementation will take approximately two months, and anticipates that Study enrollment will
accelerate once the refinements are complete.
Item 9.01. Financial Statements and
Exhibits.
(d) Exhibits.
|
Exhibit
99.1
|
Press
Release dated January 12, 2011
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, hereunto
duly authorized.
|
Date: January 12,
2011
|
||
|
WORLD
HEART CORPORATION
|
||
|
By:
|
/s/ Morgan R.
Brown
|
|
|
Name:
|
Morgan
R. Brown
|
|
|
Title:
|
Executive
Vice President and Chief Financial
Officer
|